Human CD34 (hCD34)-positive cells are used currently as a source for hematopoietic transplantation in humans. However, in steady-state murine hematopoiesis, hematopoietic stem cells (HSCs) with longterm reconstitution activity are found almost exclusively in the murine CD34 (mCD34)-negative to low fraction. To evaluate the possible differences in hCD34 and mCD34 gene expression in hematopoiesis, we made transgenic mouse strains with human genomic P1 artificial chromosome clones spanning the entire hCD34 genomic locus. In all transgenic mouse strains, a vast majority of phenotypic and functional HSC populations including mCD34 ؊͞lo express the hCD34 transgene. These data strongly support the notion that hCD34 ؉ human bone marrow cells contain long-term HSCs that can maintain hematopoiesis throughout life.
H
ematopoietic stem cells (HSCs) give rise to all blood cells. CD34 is a sialomucin-like adhesion molecule that is expressed on a few percent of primitive bone marrow cells. In human bone marrow, virtually all colony-forming unit activity resides in the population expressing human CD34 (hCD34). In primates, CD34 ϩ but not CD34 Ϫ cells repopulate lethally irradiated baboons (1) . Retrovirally labeled CD34 ϩ cells are able to reconstitute multilineage hematopoiesis after transplantation in patients with myeloma or breast cancer (2) . It has been reported also that hCD34 ϩ Thy-1 ϩ cells are highly enriched for human HSCs and possess multilineage reconstitution activity in SCID-hu (severe combined immunodeficient-human) mice (3) . Therefore, hCD34 ϩ cells as well as hCD34 ϩ Thy-1 ϩ cells are used currently to reconstitute hematopoiesis in patients receiving myeloablative conditioning in autologous and allogeneic transplantation settings (4) (5) (6) .
In murine hematopoiesis, HSCs are found almost exclusively in the Thy1.1 lo Lineage(Lin) Ϫ͞lo Sca-1 ϩ population (7) . Within the Thy1.1 lo Lin Ϫ͞lo Sca-1 ϩ cells, HSC activity is enriched in a population expressing receptors for the steel factor c-Kit (8, 9) . Osawa et al. (10) reported that within the Lin Ϫ͞lo Sca-1 ϩ c-Kit ϩ population, mouse long-term HSCs are highly enriched in the murine CD34 (mCD34) Ϫ͞lo fraction. The fact that mouse long-term HSCs in steady-state bone marrow do not express significant levels of mCD34 raised an important question of whether hCD34 ϩ cells contain self-renewing long-term human HSCs. Furthermore, recent studies show that Thy1.1 lo Lin Ϫ͞lo Sca-1 ϩ HSC populations and Lin Ϫ mCD34 ϩ hematopoietic cells in murine bone marrow might contain cells capable of differentiation into hepatocytes (11) and other organs (12) . Thus, it is important to evaluate whether the expression of hCD34 mimics that of mCD34 in the hematopoietic system.
These data led us to evaluate differences in the regulation of the hCD34 and mCD34 genes. Normal transcriptional regulation of human genes has been reproduced in transgenic mice that carry large artificial chromosomes obtained from yeast, bacteria, or P1 clones (13, 14) . Because combinatorial action of multiple, proximal and long-range, cis elements is necessary for proper regulation of hCD34 expression (15), we have established several mouse lines harboring human genomic P1 artificial chromosome (PAC) clones containing the entire hCD34 gene including all exons, introns, and more than 18 kb of flanking 5Ј and 3Ј genomic sequences. In the present experiments, we performed detailed phenotypic and functional analyses of long-term HSCs in the hCD34 transgenic mice and found that the hCD34 transgene is expressed in long-term mCD34 Ϫ͞lo HSCs. These data support the clinical use of hCD34 ϩ cells as a source for hematopoietic transplantation in humans.
Methods
Mice. hCD34 transgenic mice were made by transducing hCD34 PAC clones. PAC88L2, PAC7H11, and PAC54A19 were isolated from a PAC human genomic DNA library with an hCD34 probe as described (15) . To remove vector sequences, PAC88L2 was digested with SfiI, and PAC7H11 and PAC54A19 were digested with MluI. To obtain a construct containing 48 and 31 kb of 5Ј-hCD34 sequence, PAC88L2 was digested with AscI plus PvuI and MluI plus PvuI, respectively. Digested DNA was separated with field inversion gel electrophoresis (FIGE, Bio-Rad) for 17 h. After cutting out gels containing genomic DNAs, gels were digested with ␤-agarase (New England Biolabs). DNAs were purified and then suspended in 1 mM Tris⅐HCl (pH 7.6)͞0.1 mM EDTA. DNAs were injected into fertilized oocytes of C57B6 or FVB͞N mice and implanted into uteri of pseudopregnant C57B6 or FVB͞N mice according to standard procedures. All experiments were performed by using procedures described in the protocol approved by our Institutional Animal Care and Use Committee. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
common myeloid progenitors (CMPs), granulocyte͞monocyte progenitors (GMPs), megakaryocyte͞erythroid progenitors (MEPs), and other lymphoid progenitors have been described elsewhere (17, 18) . CLP, proB, and preB cells were purified as IL-7R␣ Genotyping of hCD34 Transgenic Mice. Tail DNA was digested with EcoRI (New England Biolabs) and hybridized to a 1.5-kb SacIdigested fragment including hCD34 exon 1 and the 5Ј end of intron 1. Several sets of PCR primers were used to confirm the transgene structures including one set at the 3Ј end of the hCD34 coding sequence (5Ј-AGAAGAGATGAGGTGTGAGGAT-3Ј and 5Ј-GGATCCACAAGAATGAGCATGTA-3Ј). To amplify a 500-bp genomic DNA fragment located at Ϫ55 kb, the primers used were 5Ј-ATCCCCTCTGCCTCTTTTTGGTG-3Ј and 5Ј-AGCCGCT-GCTACTGACTTATTGA-3Ј. To amplify a 500-bp genomic DNA fragment located at Ϫ38 kb, the primers used were 5Ј-ATGGGTGTAGGACCTGAAGTGGT-3Ј and 5Ј-TGGATTG-CATAGTTTTTGTTTCC-3Ј. To amplify a 500-bp genomic DNA fragment located at Ϫ10 kb, the primers used were 5Ј-GTGCTTTCATGGAGAGGGTTTTA-3Ј and 5Ј-TAAGACCT-CAAGGGGTTGGACTC-3Ј.
Results

The hCD34 Transgene Is Expressed in a Majority of Long-Term HSCs
Phenotypically Defined by Different Criteria. We reported that an hCD34 minigene including 4.5 kb of 5Јϩ and 3 kb of 3Ј-flanking sequence failed to express in murine multipotential lines or transgenic mice (15) . In contrast, a 141-kb genomic fragment encompassing 90 kb of 5Ј-and 26 kb of 3Ј-flanking hCD34 sequences contained regulatory elements for CD34 mRNA expression in murine stable lines and transgenic mice. We found that regulatory elements located between Ϫ18 and Ϫ10 kb 5Ј and͞or between ϩ17 and ϩ26 kb 3Ј downstream of hCD34 are required for transgenic expression (unpublished data). We have tested a number of PAC clones containing large genomic sequences containing hCD34 sequences in transgenic mouse lines to evaluate their potential for CD34 expression. All the mouse lines harboring the hCD34 transgenic constructs listed in Fig. 1a successfully expressed hCD34 . In all transgenic mouse strains, hCD34 Fig. 1b) . Therefore, the hCD34 transgene is expressed almost exclusively in immature hematopoietic cell populations in hCD34 transgenic mice.
We tested the expression of the hCD34 transgene in HSC compartments. Fig. 1c shows the phenotype of HSC compartments by five-color fluorescence-activated cell sorter analysis in 10-weekold hCD34 (PAC54A19 and PAC88L2) transgenic mice. As reported previously (10), the Lin Fig. 1a (data not  shown) .
It has been reported that long-term HSCs express a low level of Thy1.1 (7, 19) . We crossed hCD34 (PAC54A19) C57B6 (Thy-1. (Fig. 2a) . We also purified cells that are capable of exporting the intracellular dye Hoechst 33342, called the SP, which reportedly Ϫ͞lo fraction was enriched up to 33% in the SP fraction. hCD34 was expressed in Ͼ97% of the SP cells irrespective of mCD34 expression. These data suggest that the hCD34 transgene is expressed in long-term murine HSC populations defined by three independent groups (10, 16, 19) . (10) 8 (9) 9 (9) 9 (9) 9 (9) 9 (9) 9 (9) 9 (9) 9 (9) mCD34 ϩ hCD34 ϩ 100 10 1 (10) 4 (9) 0 (0) 4 (10) 2 (2) 1 (4) 2 (3) 4 (10) 0 (0) 1 (7) 1 (3) 1 (7) 16 mCD34 Ϫ hCD34 ϩ 50 10 8 (9) 6 (8) 0 (0) 8 (9) 8 (8) 8 (8) 8 (8) 8 (8) 8 (8) 8 (8) 8 (8) 8 (8) HSCs declined and disappeared by 12 weeks after transplantation in a majority of cases (Fig. 3) . Table 1 summarizes the successful engraftment after competitive reconstitution. The long-term HSC potential was found almost exclusively in mCD34 It is of importance to clarify the stages at which the hCD34 transgene is down-regulated in the mouse. We recently identified and purified Lin-restricted progenitors downstream of HSCs that represent critical hematopoietic branch points including CLPs (18) and CMPs (17) , which are the earliest progenitors in the lymphoid and myeloid differentiation pathways, respectively. We also have identified MEPs and GMPs downstream of CMPs (17) . We tested the expression of hCD34 and mCD34 in these populations as well as other T and B lymphoid-committed progenitors in hCD34 transgenic mice (Fig. 4) . In myeloid differentiation pathways, all CMPs were mCD34 ϩ hCD34 ϩ . In contrast, MEPs contained Ϸ30% of mCD34 cells. These data suggest that compared with mCD34, the down-regulation of hCD34 is delayed along the megakaryocyte͞erythrocyte pathway, whereas it slightly preceded that of mCD34 along the granulocyte͞macrophage differentiation pathway (Fig. 4a) . In the lymphoid differentiation pathways, a majority of CLPs and the earliest thymic precursors expressed both hCD34 and mCD34. The expression of the hCD34 transgene in murine CLPs is reasonable, because we have found that the human bone marrow phenotypic counterpart of the murine CLP might be IL-7R unpublished data). The down-regulation of hCD34 and mCD34 in lymphoid pathways was initiated at the proT and proB stages and completed at the preT and preB stages. In the proT and proB stages, percentages of hCD34 ϩ cells were less than mCD34 ϩ cells, suggesting that down-regulation of hCD34 in lymphoid lineages occur slightly earlier than that of mCD34 (Fig. 4b) .
Discussion
Our data demonstrate that the hCD34 transgene is expressed in phenotypically and functionally defined long-term murine HSCs. (17) purified from hCD34 (PAC88L2) C57B6 transgenic mice were reanalyzed to test expression of the hCD34 transgene. A vast majority of CMPs expressed hCD34. In contrast, Ϸ30% of mCD34 Ϫ MEPs still maintain hCD34, whereas Ϸ20% of mCD34 ϩ GMPs down-regulated hCD34. (b) Purified CLPs and the earliest thymic precursor (TP) were positive for both mCD34 and hCD34. In preT and preB stages, both mCD34 and hCD34 were down-regulated completely. The percentages of hCD34 Ϫ cells were higher than those of mCD34 Ϫ cells in both proT and proB stages, suggesting that the down-regulation of the hCD34 transgene occurs slightly earlier than that of mCD34.
Furthermore, the down-regulation of hCD34 occurs slightly earlier than that in mCD34 along with granulocyte͞macrophage and lymphoid differentiation pathways. These data strongly suggest that the regulation of CD34 expression is slightly but significantly different in human and murine hematopoiesis. The proposed differential regulation of hCD34 and mCD34 is shown in Fig. 5 . In this model, a vast majority of HSCs as well as CMPs and CLPs express hCD34 in human hematopoiesis. The model is compatible with the use of hCD34-enriched cells in clinical applications requiring stem cells.
It should be noted that the definitions of HSC phenotypes we used here may not cover all HSC populations in adult mouse bone marrow. It has been reported that some long-term HSCs may change their phenotypes according to alterations of the hematopoietic microenvironment, including hematopoietic stress, in both mice and humans. For example, the murine c-Kit Ϫ fraction in steady-state bone marrow reportedly contains some HSCs with long-term reconstitution activity at a very low frequency (20) . It is possible that the HSC activity in the c-Kit Ϫ fraction may be caused by occasional down-regulation of c-Kit in a minor fraction of HSCs, because c-Kit down-regulation can occur in HSCs after 5-fluorouracil treatment (21, 22) . Likewise, murine long-term HSCs may up-regulate mCD34 after transplantation (12) or after treatment with cytokines (23, 24) or 5-fluorouracil (25) . It has been reported also that murine long-term HSCs are increasingly restricted to the mCD34 Ϫ fraction with aging (26) . Our data indicate that in the steady-state murine bone marrow, long-term HSCs reside almost exclusively within the mCD34 Ϫ fraction irrespective of aging from 4 to 16 weeks and therefore suggest that hCD34 ϩ human bone marrow cells should contain a majority of human counterparts for murine long-term HSCs in steady-state adult bone marrow.
Xenotransplantation assays have been developed to measure human HSC activity in vivo. These assays include reconstitution assays using immunodeficient nonobese diabetic͞severe combined immunodeficient mice (27) and in utero transplantation assays in sheep (28) . Although these systems are very useful for evaluating differentiation activity of human progenitor͞stem cells, engraftment is considerably inefficient. The hCD34 Ϫ fraction as well as the hCD34 ϩ fraction reportedly contain cells of long-term differentiation potentials at a very low frequency evaluated by these systems (27, 28) . The detailed phenotype of the hCD34 Ϫ HSC population in humans is still not well described. Our data suggest that these hCD34 5 . Proposed differential regulation of human and murine CD34 in steadystate hematopoiesis. In steady-state human bone marrow, we propose that a majority of long-term HSCs express hCD34. In contrast, in murine hematopoiesis, mCD34 is down-regulated in the long-term HSCs, although mCD34 may be up-regulated in some fraction of long-term HSCs because of a variety of activation signals. hCD34 expression is maintained at the CMP and CLP stages. The down-regulation of hCD34 occurs earlier as compared with mCD34 in the granulocyte͞macrophage and lymphoid differentiation pathways but occurs later in the megakaryocyte͞erythrocyte pathway.
